Uveitis News and Research

RSS

Uveitis is an inflammation of the uvea. The uvea is the front part of the eye. It includes the iris, which is the colored part of the eye, and the parts right next to and behind the iris. Uveitis may hurt a lot of parts of the eye. It may last as long as six weeks, or it may last a shorter time.

FDA approves Actonel (risedronate sodium) for postmenopausal osteoporosis

The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of Actonel (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis.

24 Apr 2008

Age Intervention Eyelash products seized by U.S. Marshals

At the request of the U.S. Food and Drug Administration, U.S. Marshals seized today 12,682 applicator tubes of Age Intervention Eyelash, a product that may, in some users, lead to decreased vision.

19 Nov 2007

Eyelash growth product can damage vision

American consumers are being warned by the Food and Drug Administration (FDA) about the dangers of a product which promises to increase eyelash growth.

19 Nov 2007

Potential new therapy for uveitis

An inflammatory eye condition that is one of the world's leading causes of blindness could be treated much more effectively and easily thanks to a new discovery here.

29 Sep 2007

Sirion Therapeutics starts phase III clinical trials of pipeline compounds

Sirion Therapeutics has announced that it has initiated new phase III clinical programs for two of its pipeline compounds, ST-601 (difluprednate) and ST-603 (cyclosporine).

2 May 2007

Aston Academy investigates macular oedema

Aston Academy of Life Sciences, the clinical research hospital of Aston University, has recently been commissioned to assess the efficacy and safety of a specialist drug, Posurdex (Allergan Ltd, UK), which is used in the treatment of patients who suffer from a sight threatening condition, called macular oedema.

26 Jan 2006

Immunosuppressive drug mycophenolate mofetil may be effective in controlling inflammatory eye diseases

The immunosuppressive drug mycophenolate mofetil, used to prevent rejection of transplanted hearts, kidneys and livers, may also be effective in controlling inflammatory eye diseases, according to a study by Johns Hopkins' Wilmer Eye Institute.

4 Sep 2005

New treatment improves visual acuity score of patients with retinitis pigmentosa

Neurotech SA announced positive results from an open-label Phase I clinical trial (03-EI-0234) of its lead product, NT-501. NT-501 uses Neurotech’s patented Encapsulated Cell Technology (ECT) as a device to deliver ciliary neurotrophic factor (CNTF) to eyes of visually impaired patients with retinitis pigmentosa (RP). Neurotech is a biotechnology company specializing in the development of novel therapeutics to treat diseases of the eye. The company is headquartered in Paris.

8 May 2005

Uveitis News and Research

Further Reading

FDA approves Actonel (risedronate sodium) for postmenopausal osteoporosis

Age Intervention Eyelash products seized by U.S. Marshals

Eyelash growth product can damage vision

Potential new therapy for uveitis

Sirion Therapeutics starts phase III clinical trials of pipeline compounds

Aston Academy investigates macular oedema

Immunosuppressive drug mycophenolate mofetil may be effective in controlling inflammatory eye diseases

New treatment improves visual acuity score of patients with retinitis pigmentosa

Breaking Barriers: ANDYSMANCLUB's Fight for Men's Mental Health on World Mental Health Day

Arrayed CRISPR Screening for Revolutionizing Target Discovery

Innovations in baculovirus–insect cell expression systems

Latest News